12:00 AM
Dec 23, 2013
 |  BC Week In Review  |  Company News  |  Deals

Endo, NuPathe deal

Endo will acquire specialty pharma NuPathe for $2.85 per share in cash up front, or about $105 million based on fully diluted shares outstanding, plus milestones. The upfront price is a 24% premium to NuPathe's close of $2.30 on Dec. 13, the last trading day before...

Read the full 208 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >